

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification: A61K 31/44, 31/415	A1	(11) International Publication Number: WO 96/31213 (43) International Publication Date: 10 October 1996 (10.10.96)
(21) International Application Number: PCT/US96/04355 (22) International Filing Date: 29 March 1996 (29.03.96) (30) Priority Data: 08/416,275 4 April 1995 (04.04.95) US (60) Parent Application or Grant (63) Related by Continuation US 08/416,275 (CON) Filed on 4 April 1995 (04.04.95) (71) Applicant (for all designated States except US): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): DAVE, Kaushik, J. [GB/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). WILLIAMS, James, B. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). (74) Common Representative: MERCK & CO., INC.; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).		(81) Designated States: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: PHARMACEUTICAL COMPOSITION CONTAINING PROTON PUMP INHIBITORS (57) Abstract The present invention is concerned with an oral pharmaceutical formulation containing a proton pump inhibitor (PPI) which is suitable for the treatment of gastric acid related diseases in man and animals. More specifically, the composition is a paste, and is particularly suitable for delivery of a proton pump inhibitor to horses.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

- 1 -

TITLE OF THE INVENTION**PHARMACEUTICAL COMPOSITION CONTAINING PROTON
PUMP INHIBITORS****5 SUMMARY OF THE INVENTION**

The present invention provides a stable oral pharmaceutical composition in a paste form containing a proton pump inhibitor as the active ingredient. The composition is useful for delivery of acid labile drugs to animals, particularly horses, and humans with difficulty in
10 swallowing solid dosage forms such as tablets and capsules.

BACKGROUND OF THE INVENTION

Proton pump inhibitors (PPI) are potent inhibitors of gastric acid secretion by inhibiting $H^+K^+-ATPase$, the enzyme involved in the
15 final step of hydrogen ion production in the parietal cells. Hence, PPI have been used in the treatment of gastric acid related diseases in humans. These diseases include gastric and duodenal ulcers. Peptic ulcers are common also in some animals, particularly in horses. Although the etiology of gastro-duodenal ulcers in horses has not been
20 ascertained, it appears that stress plays an important roles in some cases.

PPIs are highly acid labile and hence oral formulations are enteric-coated. Enteric coated formulations are expensive and time consuming to manufacture, and requires elaborate technology and equipment. Another disadvantage of enteric coated formulation is its
25 moisture sensitivity.

WO94/25070 discloses oral composition containing a proton pump inhibitor in the form of enteric coated dry particles mixed with a dry gelling agent, the mixture may then be made into a paste-like gel prior to administration. The composition therefore requires enteric
30 coating, with the afore-mentioned disadvantages associated with such formulation. Furthermore, because such a moist gel is not stable during long-term storage at room temperature it cannot be manufactured and

- 2 -


sold as a ready-to-use formulation, rather it must be prepared *ex tempore* at the time of administration, making it inconvenient to use.

The formulation described herein is a stable, ready to use semi-solid paste formulation containing a proton pump inhibitor suitable for administering to animals such as horses, cattle, pig etc, and human beings with difficulty swallowing solid dosage forms such as tablets and capsules. The present invention can be easily administered to horses and is readily accepted by these animals. The formulation of the present invention is stable during long-term storage at room temperature.

DETAILED DESCRIPTION OF THE INVENTION


The present invention provides a stable, ready-to-use oral pharmaceutical paste composition of PPI which can be readily administered to animals such as horses. More particularly, the present composition comprises: one or more proton pump inhibitors, a hydrophobic oily liquid vehicle, a basifying agent, and a thickening agent.

The proton pump inhibitors used in the present invention are compounds of the general formula




I

wherein R_a is




- 3 -

R¹ and R³ are independently selected from hydrogen, lower alkyl, lower alkoxy and halogen, R² is selected from hydrogen, lower alkyl, lower alkoxy, lower alkoxy-lower alkoxy, lower fluoralkoxy and




5

R⁴ and R⁵ are independently selected from lower alkyl,
A is



10


R⁶ and R⁷ are independently selected from hydrogen, lower alkyl, lower alkoxy, lower fluoroalkoxy, lower fluoroalkyl, halogen,




15 wherein R⁸ is lower alkyl or lower alkoxy.

Examples of proton pump inhibitors according to Formula I
are


- 4 -




Omeprazole



Lanzoprazole




Pantoprazole




E — 3810

- 5 -



Leminoprazole



S — 4216

The preferred proton pump inhibitor used in the present invention is the compound known as omeprazole. The proton pump inhibitors used in the present invention are known compounds in the art. and methods for their preparation may be found in the literature. For example, omeprazole is disclosed in EP 5129, lansprazole in EP 174,726, pantoprazole in EP 166,287 and leminoprazole in GB 2,163,747.

The hydrophobic oily liquid vehicle may be any pharmaceutically acceptable oil that are insoluble or practically insoluble in water; examples include mineral oil, almond oil, cottonseed oil, ethyl oleate, isopropyl myristate, isopropyl palmitate, myristyl alcohol, octyldodecanol, olive oil, penut oil, safflower oil, sesame oil, soybean oil and squalene. The preferred hydrophobic oily liquid is one or more triglycerides of C₆-C₁₈ carboxylic acid; the preferred triglyceride is capric triglyceride or caprylic triglyceride, or a mixture thereof such as the product under the name Miglyol 810® (Huls America, Inc., New Jersey).

The thickening agent may be any pharmaceutically acceptable thickener that are insoluble or practically insoluble in water;

- 6 -

examples include silicone dioxide, waxes such as castor wax or hydrogenated castor oil, paraffin, cetostearyl alcohol, and the like. The preferred hydrophobic thickener is hydrogenated castor oil.

5 Suitable basifying agents are for example pharmaceutically acceptable amine bases such as triethanolamine, or salts of carboxylic acids such as sodium acetate, sodium citrate, potassium sorbate, and the like. Preferred basifying agent is potassium sorbate.

The present composition may include additional ingredients commonly used in the formulation of human and veterinary medicines.
10 For example, flavoring agents such as caramel, carrot, apple, and sausage flavors; coloring agents such as iron oxide, titanium dioxide, aluminum lakes; sweeteners such as sugar, sodium saccharin; preservatives such as parabens; antioxidants such as BHT, BHA and viscosity regulating agents such as white wax or synthetic waxes such as glyceryl tribehenate,
15 glyceryl trimyristate, hydrogenated coco-glycerides can be added.

The composition of the present invention may be prepared by dispersing the active ingredient, the proton pump inhibitor, in powder form in the hydrophobic liquid vehicle containing any other excipients except the thickening agent. The thickening agent is then added to the
20 mixture and mixed to achieve the desired consistency. The paste formulation thus obtained may be used to fill dosing syringes, which may be used directly to administer the active drug to an animal in need of treatment

The amount of the proton pump inhibitor can vary from 1 to
25 35 percent w/w in the final composition, preferably from about 1 to about 25 % w/w. The thickening agent comprises approximately 2 to 9 percent of the final composition; preferably, it is about 5 to 7 % w/w. The hydrophobic vehicle is present as approximately 60 to 95 percent, depending on the amount of other excipients in the paste. The basifying
30 agent is used in an amount sufficient to provide a non-acidic environment for the acid-labile proton pump inhibitors; typically, the amount of basifying agent is from about 0.01 to about 2 % w/w, and 0.1% is usually sufficient.

- 7 -

The incorporation of acid labile drug substance in this formulation results in an orally palatable and pharmaceutically stable paste. The invention and the pharmacologically active ingredient remain stable.

5 The composition of the present invention are useful in the treatment of peptic ulcer diseases in humans or animals. It can be used to deliver acid labile drugs orally for systemic activity in animals. The composition can also be used for the delivery of the acid labile drugs in human with difficulty of swallowing solid dosage forms such as enteric
10 coated tablets and capsules. The composition may be administered directly into the mouth of an animal, such as a horse, in need of anti-ulcer therapy; preferably a paste dosing syringe is used to facilitate drug administration. The consistency of this paste is such that it can not easily drip out or be expelled once it is deposited on the dorsal part of the
15 animal's tongue. The paste is practically free of air bubbles which enhances dosing accuracy. Another advantage of this formulation is that individualized doses can be administered.

 The amount of the composition to be administered may vary according to the particular animal species to be treated, the specific active
20 ingredient in the composition, the severity of the disease, the physical condition of the afflicted animal, and other factors. A physician or veterinarian skilled in the art of ulcer treatment may readily determined the proper dosage for the specific host under treatment. In general, a dose range of from about 0.2 mg/kg to about 20 mg/kg may be used.

25 The following examples are provided to more fully illustrate the invention, and shall not be construed as limiting the scope of the invention in any manner.

EXAMPLE 1

30

Omeprazole powder	25.0 g
Capric / caprylic triglyceride	67.9 g
Potassium sorbate	0.1 g

- 8 -

Hydrogenated castor oil 7.0 g

Potassium sorbate (and, if present, additional excipients other than drug or thickener) is added to capric/caprylic triglyceride (Miglyol 810®) with mixing. Omeprazole powder is then added with mixing. Finally hydrogenated castor oil is added, and mixing continues for about 30 minutes/

EXAMPLE 2

10

Omeprazole powder	25.0 g
Capric / caprylic triglyceride	67.8 g
Mapico yellow	0.1 g
Potassium sorbate	0.1 g
Hydrogenated castor oil	7.0 g

15

Following the procedure of Example 1, omeprazole paste of the above composition is prepared.

20

EXAMPLE 3

Omeprazole powder	25.0 g
Capric / caprylic triglyceride	67.8 g
Mapico red	0.1 g
Potassium sorbate	0.1 g
Hydrogenated castor oil	7.0 g

25

Following the procedure of Example 1, omeprazole paste of the above composition is prepared.

30

EXAMPLE 4

Omeprazole powder 10.0 g

- 9 -

Capric / caprylic triglyceride	84.0 g
Triethanolamine	1.0 g
Silicon dioxide	5.0 g

5 Following the procedure of Example 1, omeprazole paste of the above composition is prepared.

EXAMPLE 5

10	Omeprazole powder	22.0 g
	Capric / caprylic triglyceride	67.8 g
	BHT	0.01g
	Mapico Yellow	0.1 g
	Potassium sorbate	0.1 g
15	Hydrogenated castor oil	7.0 g

 Following the procedure of Example 1, omeprazole paste of the above composition is prepared.

20

- 10 -

WHAT IS CLAIMED IS:

1. A pharmaceutical composition for oral administration which comprises: a proton pump inhibitor, a thickening agent, a basifying agent, and a hydrophobic oily liquid vehicle.
5
2. A composition of Claim 1 wherein said proton pump inhibitor is omeprazole.
- 10 3. A composition of Claim 1 wherein said thickening agent is hydrogenated castor oil.
- 15 4. A composition of Claim 1 wherein said hydrophobic liquid vehicle is capric/caprylic triglyceride.
5. A composition of Claim 2 wherein said basifying agent is potassium sorbate.
- 20 6. A composition of Claim 1 wherein said proton pump inhibitor is about 1 to about 35% by weight, and the thickening agent is about 2 to about 9% by weight.
- 25 7. A composition of Claim 6 wherein said proton pump inhibitor is omeprazole, said thickening agent is hydrogenated castor oil, and the hydrophobic liquid vehicle is capric/caprylic triglyceride.
- 30 8. A composition of Claim 1 wherein said proton pump inhibitor is omeprazole, said thickening agent is hydrogenated castor oil, said hydrophobic oil is capric/caprylic triglyceride, and said basifying agent is potassium sorbate.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US96/04355

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 31/44, 31/415

US CL : 514/338, 398

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/338, 398

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US, A, 5,093,342 (TOMOI ET AL.) 03 March 1992	1-8
A	US, A, 5,124,158 (RUWART ET AL.) 23 June 1992	1-8
A	US, A, 5,219,870 (KIM) 15 June 1993	1-8

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:	* T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
* A* document defining the general state of the art which is not considered to be of particular relevance	* X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
* E* earlier document published on or after the international filing date	* Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
* L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	* &*	document member of the same patent family
* O* document referring to an oral disclosure, use, exhibition or other means		
* P* document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search
28 MAY 1996Date of mailing of the international search report
24 JUN 1996Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

RAYMOND J. HENLEY III

Telephone No. (703) 308-1235

Form PCT/ISA/210 (second sheet)(July 1992)*

THIS PAGE BLANK (USPTO)